MedTrace Logo

A Study to Investigate the Absorption, Metabolism and Excretion of [14C]-BGB-11417

NCT05844111 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2025-04-17

No results posted yet for this study

Summary

The main objective of this study is to determine the mass balance, routes of elimination, and pharmacokinetics of \[14C\]-BGB-11417 in healthy male participants along with determining the concentrations of radioactivity in plasma, fecal and urinary elimination of total radioactivity.

Conditions

  • Healthy Volunteers

Interventions

DRUG

[14C]-BGB-11417

A single oral dose of liquid formulation

Sponsors & Collaborators

  • BeiGene

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-22
Primary Completion
2023-06-18
Completion
2023-06-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05844111 on ClinicalTrials.gov